Combining ivonescimab with chemotherapy for treating colorectal cancer liver metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of ivonescimab in combination with chemotherapy for patients with initially unresectable colorectal cancer liver metastases. Participants will receive the treatment every three weeks for up to eight cycles, with regular clinic visits for monitoring and assessments. The study will focus on measuring the objective response rate and assessing the safety profile of the treatment. The ultimate goal is to determine if this combination can improve treatment outcomes for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years.
2. Histologically confirmed colorectal adenocarcinoma.
3. Radiologically confirmed liver-only metastases. Patients with ≤1 cm extrahepatic lesions not confirmed as metastatic are eligible.
4. No prior systemic therapy or local therapy for metastatic lesions, or completion of neoadjuvant/adjuvant chemotherapy ≥6 months before diagnosed disease recurrence.
5. Liver metastases considered unresectable or borderline resectable by multidisciplinary evaluation.
6. Liver metastases were measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
7. Eastern Cooperative Oncology Group performance status 0-1
8. Life expectancy ≥12 weeks.
9. No contraindications to hepatic resection/ablation, and primary tumor resectable or previously resected.
10. Adequate organ function as determined by normal bone marrow function (hemoglobin ≥80 g/L, absolute neutrophil count ≥1.5×10⁹/L, and platelets ≥100×10⁹/L), renal function (serum creatinine ≤1.5×upper limit of normal \[ULN\] and creatinine clearance ≥30 mL/min), liver function (serum bilirubin ≤2×ULN and serum transaminases ≤5×ULN).

Exclusion Criteria:

1. Definite extrahepatic metastases.
2. dMMR or MSI-H colorectal cancer.
3. Intolerance to the study drug during prior neoadjuvant/adjuvant therapy.
4. Toxicities from prior therapy have not resolved to ≤ Grade 1 (according to NCI-CTCAE v5.0), except for alopecia (any grade) and peripheral neuropathy (≤ Grade 2).
5. History of or concurrent other malignancies within the past 5 years, except cured localized tumors.
6. Surgery performed within 28 days prior to enrollment.
7. Hypertension with systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg despite antihypertensive treatment.
8. Major cardiovascular events within 12 months prior to enrollment.
9. History of severe bleeding tendency or coagulation disorders; tumor encasement of major blood vessels or significant necrosis or cavitation, and the investigator deems participation in the study may pose a bleeding risk.
10. Active autoimmune disease requiring systemic treatment within the past 2 years.
11. History of immunodeficiency, positive HIV antibody test, or long-term use of corticosteroids or other immunosuppressants.
12. Prior history of allogeneic bone marrow or organ transplantation.
13. Received live vaccines within 30 days prior to the first dose or plans to receive live vaccines during the study period.
14. Allergy to any component of the study drugs; history of severe hypersensitivity reactions to other monoclonal antibodies.
15. Women who are pregnant or breastfeeding.
16. Severe comorbidities or any other condition that precludes safe administration of the study treatment, including but not limited to symptomatic congestive heart failure (Class II or higher per NYHA classification), unstable angina, acute myocardial ischemia, poorly controlled arrhythmias, decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, or psychiatric/social conditions that may limit compliance with study requirements or impair the subject's ability to provide written informed consent.
17. Any other condition deemed by the investigator as unsuitable for participation in this study.

Where it's running

• National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
  Beijing, China Recruiting

Study contacts

• Study coordinator: Lin Yang
• Email: linyangcicams@126.com
• Phone: 8613681015148

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ivonescimab with pemetrexed and platinum chemotherapy as first-line treatment for advanced malignant pleural mesothelioma

  This study tests whether adding ivonescimab to standard pemetrexed plus platinum-based chemotherapy can help people with newly diagnosed advanced malignant pleural mesothelioma.

  Recruiting at 3 sites Phase 1/2 Ruijin Hospital · Shanghai, Shanghai Municipality and 2 other locations · NCT07885319

• Ivonescimab with GEMOX as neoadjuvant and conversion therapy for biliary tract cancer

  This study tests whether adding Ivonescimab to GEMOX can help patients with biliary tract cancer shrink tumors before surgery or enable conversion to operable disease.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07854600

• Multimodal Survival Predictor for Colorectal Liver Metastases After Surgery

  Researchers are testing a tool that combines MRI-derived tumor features with clinical data to predict survival after surgery for colorectal liver metastases.

  Recruiting Anhui Provincial Hospital · Hefei, Anhui · NCT07830576

• Ivonescimab plus enfortumab vedotin vs pembrolizumab plus enfortumab vedotin in untreated locally advanced or metastatic urothelial cancer

  This trial tests if adding ivonescimab to enfortumab vedotin works better than pembrolizumab plus enfortumab vedotin for people with untreated locally advanced or metastatic urothelial cancer.

  Recruiting at 2 sites Phase 2/3 Summit Therapeutics · Phoenix, Arizona and 6 other locations · NCT07815665

• Ivonescimab as first-line treatment for PD-L1 positive, driver gene-negative advanced NSCLC

  This real-world study tests whether Ivonescimab given as a first-line therapy helps patients with PD-L1 positive, driver gene-negative advanced NSCLC succeed with treatment and manage safety.

  Recruiting Guangdong Association of Clinical Trials · Guangzhou, Guangdong · NCT07696832

• Ivonescimab in advanced cutaneous angiosarcoma: a first look

  This Phase 2 pilot tests ivonescimab in adults with advanced or metastatic cutaneous angiosarcoma who have already had taxane-based chemotherapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07655570

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.